1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > European Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free injectors, Auto-injectors, Nasal sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts to 2017

European Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free injectors, Auto-injectors, Nasal sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts to 2017

The European drug delivery market was worth $39.9 billion in the year 2012. The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies, to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

Patent expiries of certain blockbuster drugs, growing demand for self-administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer and growing focus on pediatric and geriatric patients are accelerating the growth of this market. However, drug failures and recalls and technical barriers are estimated to hamper the growth of this market. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

The growing number of elderly persons is a large consumer of home care drug delivery devices. Expanding applications of drug delivery into niche therapeutic areas, strategic collaborations and self-administration and home care drug delivery devices represent vast opportunities for key players in this market. According to a 2012 report published by the World Economic Forum (WEF), the total geriatric population of Switzerland (aged 60 years and older) was 23% of the total population. This number is expected to increase to 32% by 2030 and to 37% by 2050. An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.

The geographies covered in this study are Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe (RoE). Germany is the largest market for drug delivery, followed by France and the U.K. However, these countries are expected to grow at a slower pace than Russia and RoE, primarily due to a certain amount of saturation in the market. The latter markets are poised to register maximum growth over the next five years, owing to the expansion of these economies, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.

Scope of the Report

This research report categorizes the European drug delivery market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery markets is comprehensively analyzed at a granular level by geography (Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe) to provide in-depth information on the European scenario of this market.

European drug delivery market, by technologies

Oral
Controlled Release
Orodispersible Tablets (ODT) and Taste Masking
Others
Pulmonary
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Transdermal
- Passive
Reservoir System
Matrix System
- Active
Iontophoresis
Microporation
Others
Injectable
- Conventional Injection Devices
Fillable Syringes
Prefilled Syringes
- Self-injection Devices
Needle-free Injectors
Auto-injectors or Safety Syringe Devices
Pen Injectors
- Others
Ocular
Eye Drops
Ointment and Gel
Others
Nasal
Nasal Drops
Nasal Sprays
Nasal Inhalers
Others
Topical
Liquid Formulations
Semi-solid Formulations
Solid Formulations
Implantable
Drug Eluting Stents
Implantable Infusion Pumps
Intravitreal Implants
Brachytherapy Seeds
Contraceptive Implants
Transmucosal
Oral (Buccal and Sublingual)
Others (Rectal and Vaginal)

Geographic analysis

Germany
France
United Kingdom
Spain
Italy
Russia
Rest of Europe (RoE)

Customer Interested in this report also can view

Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017

Table Of Contents

European Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free injectors, Auto-injectors, Nasal sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts to 2017
TABLE OF CONTENTS

1 INTRODUCTION 22

1.1 KEY TAKE-AWAYS 22
1.2 REPORT DESCRIPTION 23
1.3 MARKETS COVERED 24
1.4 STAKEHOLDERS 26
1.5 RESEARCH METHODOLOGY 26
1.5.1 MARKET SIZE 26
1.5.2 MARKET SHARE 27
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 27
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 27
1.5.5 ASSUMPTIONS 28

2 EXECUTIVE SUMMARY 29

3 MARKET OVERVIEW 34

3.1 INTRODUCTION 35
3.2 MARKET DYNAMICS 35
3.2.1 DRIVERS 35
3.2.1.1 Patent Cliff and Increased Competition to Increase Adoption Rate 35
3.2.1.2 Improving Patient Compliance and Acceptability, an Impetus to the Drug Delivery Systems Market 37
3.2.1.3 Increasing Focus on Pediatric and Geriatric Patients to Boost Overall Growth 37
3.2.1.4 Increasing Incidence of Chronic Diseases like Cancer and Diabetes to Enhance Demand for Drug Delivery Technologies 38
3.2.1.5 Higher Premature Mortality Rates in Eastern Europe and Russia Suggests need for Better Medication 39
3.2.2 RESTRAINTS 39
3.2.2.1 Drug Failures and Recalls Mar Market Growth 39
3.2.2.2 Technical Barriers Restrict Growth 40
3.2.3 OPPORTUNITIES 41
3.2.3.1 Collaborations Between Pharmaceutical Companies and Drug Delivery Firms 41
3.2.3.2 Self-administration and Home Care Drug Delivery Devices 42
3.2.3.3 Expanding Therapeutic Applications of Drug Delivery Technologies 43
3.2.4 TARGETED DRUG DELIVERY 43
3.2.4.1 Passive Systems Contribute 60% to the Targeted Drug Delivery Market 43
3.2.4.2 Active Targeted Drug Delivery has Major Applications in Cancer Therapy 44
3.2.4.3 Companies Focus on Novel Targeted Drug Delivery 44
3.2.5 BURNING ISSUES 45
3.2.5.1 Striking Right Partnerships 45
3.2.5.2 Improving the Bioavailability of Drugs 46
3.3 REGULATORY AFFAIRS 47
3.3.1 EUROPEAN UNION REGULATORY FRAMEWORK 47
3.3.2 GERMANY 48
3.3.2.1 Bundesministerium für Gesundheit
(Ministry of Health) 48
3.3.2.2 Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) 48
3.3.3 U.K. 49
3.3.3.1 The Medicines and Healthcare products Regulatory Agency (MHRA) 49
3.3.4 FRANCE 49
3.3.4.1 Agence Nationale de Securite du Medicament et des Produits de Sante (National Agency for the Safety of Medicines and Health Products) 50
3.3.5 SPAIN 50
3.3.5.1 Agencia Espagnola de Medicamentos y Productos Sanitarios (Spanish Medicines and Health Products Agency) 50
3.3.6 ITALY 51
3.3.6.1 Agenzia Italiana del Farmaco
(Italian Medicines Agency) 51
3.3.7 RUSSIA 51
3.3.7.1 Association of International Pharmaceutical Manufacturers (AIPM) 51
3.4 REIMBURSEMENT SCENARIO IN THE EUROPEAN UNION 52
3.5 MARKET SEGMENTATION 53
3.6 PORTER'S FIVE FORCES ANALYSIS 55
3.7 VALUE CHAIN ANALYSIS 58
3.8 MARKET SHARE ANALYSIS 59
3.8.1 PULMONARY DRUG DELIVERY 59
3.8.2 INJECTABLE DRUG DELIVERY 60
3.8.2.1 Conventional Injection Devices 60
3.8.2.2 Self-injection Devices 62

4 GLOBAL DRUG DELIVERY MARKET, BY TECHNOLOGY 64

4.1 INTRODUCTION 65
4.2 OPPORTUNITY MATRIX 67
4.3 ORAL DRUG DELIVERY 68
4.3.1 CONTROLLED RELEASE 71
4.3.2 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING 73
4.3.3 OTHERS 74
4.4 PULMONARY DRUG DELIVERY 76
4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY 77
4.4.2 METERED DOSE INHALERS (MDI) 80
4.4.3 DRY POWDER INHALERS (DPI) 82
4.4.4 NEBULIZERS 83
4.5 TRANSDERMAL DRUG DELIVERY 85
4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY 88
4.5.1.1 Matrix System 90
4.5.1.2 Reservoir System 90
4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY 90
4.5.2.1 Microporation 92
4.5.2.2 Iontophoresis 93
4.5.2.3 Others 94
4.6 INJECTABLE DRUG DELIVERY 94
4.6.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 97
4.6.1.1 Fillable 99
4.6.1.2 Prefilled 100
4.6.2 SELF-INJECTION DEVICES 101
4.6.2.1 Pen Injectors 104
4.6.2.2 Needle-free Injectors 105
4.6.2.3 Auto Injectors 105
4.6.3 OTHERS 106
4.7 OCULAR DRUG DELIVERY 108
4.7.1 EYE DROPS 111
4.7.2 OINTMENTS AND GELS 112
4.7.3 OTHERS 114
4.8 NASAL DRUG DELIVERY 116
4.8.1 NASAL SPRAYS 118
4.8.2 NASAL INHALERS 120
4.8.3 NASAL DROPS 121
4.8.4 OTHERS 123
4.9 TOPICAL DRUG DELIVERY 124
4.9.1 SEMI-SOLID FORMULATIONS 126
4.9.2 LIQUID FORMULATIONS 128
4.9.3 SOLID FORMULATIONS 129
4.10 IMPLANTABLE DRUG DELIVERY 131
4.10.1 DRUG- ELUTING STENTS 134
4.10.2 IMPLANTABLE INFUSION PUMPS 136
4.10.3 CONTRACEPTIVE IMPLANTS 137
4.10.4 INTRAOCULAR IMPLANTS 139
4.10.5 BRACHYTHERAPY SEEDS 141
4.11 TRANSMUCOSAL DRUG DELIVERY 143
4.11.1 ORAL (BUCCAL AND SUBLINGUAL) 146
4.11.2 OTHERS (RECTAL, VAGINAL) 147

5 GEOGRAPHIC ANALYSIS 150

5.1 INTRODUCTION 150
5.2 GERMANY 151
5.3 FRANCE 162
5.4 U.K. 173
5.5 SPAIN 184
5.6 ITALY 196
5.7 RUSSIA 207
5.8 REST OF EUROPE (ROE) 218

6 COMPETITIVE LANDSCAPE 230

6.1 INTRODUCTION 230
6.2 NEW PRODUCT LAUNCH 231
6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES and PARTNERSHIPS 233
6.4 MERGERS and ACQUISITIONS 235
6.5 OTHER DEVELOPMENTS 236

7 COMPANY PROFILES 240

7.1 3M COMPANY 240
7.2 ALKERMES, INC. 246
7.3 BECTON, DICKINSON AND COMPANY 252
7.4 CIMA LABS 258
7.5 DALI MEDICAL DEVICES 264
7.6 FOAMIX 267
7.7 JOHNSON and JOHNSON, INC. 270
7.8 PSIVIDA CORPORATION 277
7.9 SKYEPHARMA PLC 281
7.10 VALEANT PHARMACEUTICALS 286
7.11 YPSOMED HOLDING AG 294



LIST OF TABLES

TABLE 1 EUROPEAN DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017($BILLION) 30
TABLE 2 EUROPEAN DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017($BILLION) 66
TABLE 3 EUROPEAN ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 69
TABLE 4 EUROPEAN ORAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 70
TABLE 5 EUROPEAN CONTROLLED RELEASE DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 72
TABLE 6 EUROPEAN ODT andTASTE-MASKING MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 74
TABLE 7 EUROPEAN OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 75
TABLE 8 EUROPEAN PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 78
TABLE 9 EUROPEAN PULMONARY DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 79
TABLE 10 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES 80
TABLE 11 EUROPEAN METERED DOSE INHALATION (MDI) MARKET,
BY COUNTRY,2010 - 2017 ($MILLION) 81
TABLE 12 EUROPEAN DRY POWDER INHALATION (DPI) MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 83
TABLE 13 EUROPEAN NEBULIZERS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 84
TABLE 14 EUROPEAN TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 86
TABLE 15 EUROPEAN TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 87
TABLE 16 EUROPEAN PASSIVE TRANSDERMAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE, 2010 - 2017 ($MILLION) 88
TABLE 17 EUROPEAN PASSIVE TRANSDERMAL DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 89
TABLE 18 EUROPEAN ACTIVE TRANSDERMAL DRUG DELIVERY MARKET,
BY TECHNOLOGY, 2010 - 2017 ($MILLION) 91
TABLE 19 EUROPEAN ACTIVE TRANSDERMAL DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 92
TABLE 20 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION) 95
TABLE 21 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 96
TABLE 22 EUROPEAN CONVENTIONAL INJECTION DEVICES MARKET,
BY PRODUCT, 2010 - 2017 ($MILLION) 98
TABLE 23 EUROPEAN CONVENTIONAL INJECTION DEVICES MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 99
TABLE 24 EUROPEAN SELF-INJECTION DEVICES MARKET, BY PRODUCT,
2010 - 2017 ($MILLION) 102
TABLE 25 EUROPEAN SELF-INJECTION DEVICES MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 103
TABLE 26 EUROPEAN OTHER INJECTORS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 107
TABLE 27 EUROPEAN OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 109
TABLE 28 EUROPEAN OCULAR DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 110
TABLE 29 EUROPEAN EYE DROPS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 112
TABLE 30 OINTMENT and GEL DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 113
TABLE 31 EUROPEAN OTHER OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 115
TABLE 32 EUROPEAN NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 117
TABLE 33 EUROPEAN NASAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 118
TABLE 34 EUROPEAN NASAL SPRAY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 119
TABLE 35 EUROPEAN NASAL INHALER MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 121
TABLE 36 EUROPEAN NASAL DROPS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 122
TABLE 37 EUROPEAN OTHER NASAL DELIVERY FORMULATIONS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 123
TABLE 38 EUROPEAN TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 125
TABLE 39 EUROPEAN TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 126
TABLE 40 EUROPEAN SEMI-SOLID TOPICAL FORMULATION MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 127
TABLE 41 EUROPEAN LIQUID TOPICAL FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 129
TABLE 42 EUROPEAN SOLID TOPICAL FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 130
TABLE 43 EUROPEAN IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE,
2010 - 2017 ($MILLION) 132
TABLE 44 EUROPEAN IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 133
TABLE 45 EUROPEAN DRUG-ELUTING STENTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 135
TABLE 46 EUROPEAN IMPLANTABLE INFUSION PUMPS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 137
TABLE 47 EUROPEAN CONTRACEPTIVE IMPLANTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 138
TABLE 48 EUROPEAN INTRAOCULAR IMPLANTS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 140
TABLE 49 EUROPEAN BRACHYTHERAPY SEEDS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 142
TABLE 50 EUROPEAN TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 144
TABLE 51 EUROPEAN TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 145
TABLE 52 EUROPEAN ORAL TRANSMUCOSAL DRUG DELIVERY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 147
TABLE 53 EUROPEAN OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 148
TABLE 54 GERMANY: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 153
TABLE 55 GERMANY: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 154
TABLE 56 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 155
TABLE 57 GERMANY: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 156
TABLE 58 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 157
TABLE 59 GERMANY: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 158
TABLE 60 GERMANY: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 159
TABLE 61 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 160
TABLE 62 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 161
TABLE 63 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 162
TABLE 64 FRANCE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 164
TABLE 65 FRANCE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 165
TABLE 66 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 166
TABLE 67 FRANCE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 167
TABLE 68 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 168
TABLE 69 FRANCE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 169
TABLE 70 FRANCE: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 170
TABLE 71 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 171
TABLE 72 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 172
TABLE 73 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 173
TABLE 74 U.K.: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 175
TABLE 75 U.K.: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 176
TABLE 76 U.K.: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 177
TABLE 77 U.K.: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 178
TABLE 78 U.K.: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 179
TABLE 79 U.K.: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 180
TABLE 80 U.K.: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 181
TABLE 81 U.K.: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 182
TABLE 82 U.K.: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 183
TABLE 83 U.K.: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 184
TABLE 84 SPAIN: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 186
TABLE 85 SPAIN: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 187
TABLE 86 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 188
TABLE 87 SPAIN: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 189
TABLE 88 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 190
TABLE 89 SPAIN: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 191
TABLE 90 SPAIN: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 192
TABLE 91 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 193
TABLE 92 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 194
TABLE 93 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 195
TABLE 94 ITALY: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 197
TABLE 95 ITALY: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 198
TABLE 96 ITALY: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 199
TABLE 97 ITALY: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 200
TABLE 98 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 201
TABLE 99 ITALY: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 202
TABLE 100 ITALY: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 203
TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 204
TABLE 102 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 205
TABLE 103 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 206
TABLE 104 RUSSIA: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 208
TABLE 105 RUSSIA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 209
TABLE 106 RUSSIA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 210
TABLE 107 RUSSIA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 211
TABLE 108 RUSSIA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 212
TABLE 109 RUSSIA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 213
TABLE 110 RUSSIA: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 214
TABLE 111 RUSSIA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 215
TABLE 112 RUSSIA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION) 216
TABLE 113 RUSSIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 217
TABLE 114 ROE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION) 220
TABLE 115 ROE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 221
TABLE 116 ROE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 222
TABLE 117 ROE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION) 223
TABLE 118 ROE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 224
TABLE 119 ROE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 225
TABLE 120 ROE: NASAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 226
TABLE 121 ROE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,
2010 - 2017 ($MILLION) 227
TABLE 122 ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,
2010 - 2017 ($MILLION) 228
TABLE 123 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION) 229
TABLE 124 NEW PRODUCT LAUNCH, 2010 - 2012 231
TABLE 125 AGREEMENTS, COLLABORATIONS, JOINT VENTURES and PARTNERSHIPS, 2011 -2012 234
TABLE 126 MERGERS and ACQUISITIONS, 2011 -2013 235
TABLE 127 OTHER DEVELOPMENTS, 2010 - 2013 237
TABLE 128 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 242
TABLE 129 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 243
TABLE 130 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 248
TABLE 131 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 253
TABLE 132 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE,
BY SEGMENT, 2010 - 2012 ($MILLION) 254
TABLE 133 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012($MILLION) 254
TABLE 134 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY SEGMENT, 2010 - 2012 ($MILLION) 260
TABLE 135 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,
BY GEOGRAPHY, 2010 - 2012 ($MILLION) 261
TABLE 136 JOHNSON and JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 272
TABLE 137 JOHNSON and JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 272
TABLE 138 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 287
TABLE 139 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 295
TABLE 140 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION) 296
TABLE 141 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2011 ($MILLION) 296



LIST OF FIGURES

FIGURE 1 EUROPEAN DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2017 31
FIGURE 2 EUROPEAN DRUG DELIVERY MARKET, BY COUNTRY,
2010 - 2017 ($BILLION) 32
FIGURE 3 MARKET DYNAMICS 36
FIGURE 4 EUROPEAN DRUG DELIVERY MARKET SEGMENTATION 53
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET 55
FIGURE 6 VALUE CHAIN ANALYSIS 58
FIGURE 7 EUROPEAN PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 59
FIGURE 8 EUROPEAN CONVENTIONAL INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 61
FIGURE 9 EUROPEAN CONVENTIONAL INJECTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 62
FIGURE 10 OPPORTUNITY MATRIX: EUROPEAN DRUG DELIVERY TECHNOLOGIES MARKET (2012) 67
FIGURE 11 KEY GROWTH STRATEGIES, 2010 - 2013 230
FIGURE 12 3M COMPANY: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 241
FIGURE 13 ALKERMES: TOTAL REVENUE AND RandD EXPENDITURE,
2009 - 2011 ($MILLION) 247
FIGURE 14 BECTON, DICKINSON: TOTAL REVENUE AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 253
FIGURE 15 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 259
FIGURE 16 JOHNSON and JOHNSON, INC.: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 271
FIGURE 17 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 - 2011 ($MILLION) 278
FIGURE 18 SKYEPHARMA PLC: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 282
FIGURE 19 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($MILLION) 287
FIGURE 20 YPSOMED: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 295

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The syringes market is expected to reach USD 15.99 billion by 2021, at a CAGR of 8.7% from 2016 to 2021. The syringes market is primarily driven by the high prevalence of chronic diseases across the globe. ...

Needle Free Injection Systems Market by Product, by Technology, Usability, Type of Medication, Delivery Site - Forecasts to 2021

Needle Free Injection Systems Market by Product, by Technology, Usability, Type of Medication, Delivery Site - Forecasts to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 billion by 2021 from USD 9.81 billion in 2016, at a CAGR of 15.5% during the forecast period. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.